Genocea Chooses Corporate VCs, Perhaps Presaging a Sale?
This article was originally published in Start Up
Executive Summary
Many start-ups downplay or shrug off the suggestion that strategic investors will help align them for exits, but for vaccine developer Genocea Biosciences, the decision to secure multiple corporate VCs in its $35 million Series B round was engineered to do exactly that.